O
0.013
0.00 (8.33%)
| Previous Close | 0.012 |
| Open | 0.013 |
| Volume | 1,044,115 |
| Avg. Volume (3M) | 7,370,483 |
| Market Cap | 49,193,040 |
| Price / Sales | 30.04 |
| Price / Book | 4.93 |
| 52 Weeks Range | |
| Earnings Date | 30 Aug 2024 |
| Operating Margin (TTM) | -640.16% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 40.60% |
| Total Debt/Equity (MRQ) | 1.49% |
| Current Ratio (MRQ) | 3.26 |
| Operating Cash Flow (TTM) | -10.82 M |
| Levered Free Cash Flow (TTM) | -6.53 M |
| Return on Assets (TTM) | -82.34% |
| Return on Equity (TTM) | -163.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (AU) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | ONCOSIL FPO [OSL] | - | - |
AIStockmoo Score
-0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | -0.50 |
|
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 13.38% |
| % Held by Institutions | 23.90% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |